Research ArticleArticle
Open Access
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
Tatiana Nevskaya, Janet E. Pope, Matthew A. Turk, Jenny Shu, April Marquardt, Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Marco Matucci-Cerinic, Murray Baron, Christopher P. Denton and Sindhu R. Johnson
The Journal of Rheumatology May 2021, jrheum.201594; DOI: https://doi.org/10.3899/jrheum.201594
Tatiana Nevskaya
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Janet E. Pope
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Matthew A. Turk
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Jenny Shu
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
April Marquardt
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Frank van den Hoogen
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Dinesh Khanna
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Jaap Fransen
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Marco Matucci-Cerinic
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Murray Baron
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Christopher P. Denton
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
Sindhu R. Johnson
This work was supported by a grant from the Scleroderma Foundation and the World Scleroderma Foundation. SRJ is supported by a Canadian Institutes of Health Research New Investigator Award and the Gurmej Kaur Dhanda Scleroderma Research Award. DK was funded by the National Institutes of Health/ National Institute of Arthritis and Musculoskeletal and Skin Diseases grant 5K24AR063120-07. T. Nevskaya, MD, PhD, J.E. Pope, MD, MPH, M.A. Turk, MSc, J. Shu, MD, HBSc, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; A. Marquardt, DO, D. Khanna, MD, MS, University of Michigan, Ann Arbor, Michigan, USA; F. van den Hoogen, MD, PhD, St. Maartenskliniek and Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; J. Fransen, MSc, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; M. Matucci-Cerinic, MD, PhD, Department of Experimental and Clinical Medicine & Division of Rheumatology AOUC, Florence Italy University of Florence, Florence, Italy; M. Baron, MD, McGill University, Division Head Rheumatology, Jewish General Hospital, Montreal, Quebec, Canada; C.P. Denton, FRCP, PhD, University College London, Division of Medicine, London, UK; S.R. Johnson, MD, PhD, Toronto Scleroderma Program, Toronto Western and Mount Sinai Hospitals, Department of Medicine, and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. The authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. S.R. Johnson, Toronto Scleroderma Program, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada. Email: Sindhu.Johnson@uhn.ca. Accepted for publication April 26, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
Tatiana Nevskaya, Janet E. Pope, Matthew A. Turk, Jenny Shu, April Marquardt, Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Marco Matucci-Cerinic, Murray Baron, Christopher P. Denton, Sindhu R. Johnson
The Journal of Rheumatology May 2021, jrheum.201594; DOI: 10.3899/jrheum.201594
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets
Tatiana Nevskaya, Janet E. Pope, Matthew A. Turk, Jenny Shu, April Marquardt, Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Marco Matucci-Cerinic, Murray Baron, Christopher P. Denton, Sindhu R. Johnson
The Journal of Rheumatology May 2021, jrheum.201594; DOI: 10.3899/jrheum.201594